D
Last Price
52 Week Range
CA$0.20 - CA$0.88
Next Earnings Date
-
Next Earnings Date
-
Last Price
Market Cap | CA$22.27M |
EV | - |
Shares Outstanding | 60.19M |
Beta | - |
Industry | - |
Analyst Rating | - |
Analyst Target Price | - |
Number of Analysts | 0 |
P/E E | - |
P/Revenue E | - |
Revenue | - |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Revenue | - |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin E | - |
Net Profit Margin E | - |
ROE E | - |
ROCE | - |
DPS E | - |
Payout Ratio E | - |
Div. Yield E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
D
DiagnosTear Technologies Inc.
DTR
Sector
Industry
CEO
Gross, Shimon
Employees
Website
diagnostear.comIPO Date
Headquarters
10 Menachem Plaut Street, Rehovot 7670621, Israel
The last closing price of DiagnosTear Technologies (DTR) is CA$0.37, reflecting a -7.50% change from the prior session. Last updated: March 7, 2026 at 7:53 PM Eastern Time
Over the last year, DiagnosTear Technologies (DTR) has established a 52-week price range between a high of CA$0.88 and a low of CA$0.20. This metric is essential for assessing the stock's annual volatility. Last updated: March 7, 2026 at 7:53 PM Eastern Time
The current DiagnosTear Technologies (DTR) market capitalization is approximately CA$22.27M, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, DiagnosTear Technologies's market cap fluctuates with changes in its share price and share count. Last updated: March 7, 2026 at 7:53 PM Eastern Time
DiagnosTear Technologies (DTR) does not currently pay a dividend. Over the last twelve months (LTM), the company paid CA$0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future.
Based on the latest available analyst coverage, DiagnosTear Technologies (DTR) currently carries a not available consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: March 7, 2026 at 7:53 PM Eastern Time
Like other publicly traded stocks, DiagnosTear Technologies (DTR) shares are bought and sold on stock exchanges such as CNSX and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for DiagnosTear Technologies (DTR) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.
At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add DTR to your watchlist.
DiagnosTear Technologies trades under the ticker symbol DTR on the CNSX stock exchange. The ticker DTR is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.
NEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data Providers